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Treatment of infrainguinal thromboembolic
complications during peripheral endovascular
procedures with AngioJet rheolytic
thrombectomy, intraoperative thrombolysis, and
selective stenting
Stavros Spiliopoulos, MD, PhD, EBIR, Konstantinos Katsanos, MD, PhD, EBIR, George Fragkos, MD,
Dimitrios Karnabatidis, MD, PhD, EBIR, and Dimitrios Siablis, MD, PhD, EBIR, Patras, Greece
Objective: This study investigated the safety and effectiveness of the infrainguinal use of the AngioJet rheolytic mechanical
thrombectomy system (Possis Medical, Minneapolis, Minn) for the treatment of acute infrainguinal thromboembolism
occurring during lower limb revascularization procedures.
Methods: For the interval between January 2000 and January 2011, our hospital’s database was meticulously searched
for all patients with acute thromboembolism that occurred during lower limb angioplasty, with or without stenting
procedures, who were treated with infrainguinal AngioJet thrombectomy. Baseline patient demographics and
procedural details were analyzed. Primary end points included technical success, defined as the complete revascu-
larization of the acutely occluded vessel; clinical success, defined as the absence of death or amputation<60 days; and
procedure-related complication. Secondary end points included embolized vessel primary patency and overall patient
survival.
Results: During this 12-year period, 3147 peripheral percutaneous procedures of angioplasty, with or without stenting,
were performed in our department. Intraoperative, clinically, and angiographically evident thromboembolism occurred
in 18 of 3147 procedures (0.57%), and 14 (77.7%) were managed using the AngioJet thrombectomy system. In total, 22
arteries were treated (13 infrapopliteal, 3 femoropopliteal, and 6 popliteal arteries). All patients had a completion
angiogram for the assessment of the runoff vessels’ status. Technical and clinical success occurred in 13 of 14 (92.8%).
Adjunctive local thrombolysis or clot trapping, or both, with stenting was used in 64.3% and 42.8% of the procedures,
respectively. Mean time follow-up was 38.1 49.0 months. The 1-year embolized vessel primary patency rate was 50.9%,
and the survival rate was 53.5% up to 11.5 years of follow-up, as estimated by Kaplan-Meier analysis. The 1-year limb
salvage rate was 92.3%. There were no procedure-related minor amputations and one (7.1%) procedure-related major
above-knee amputation.
Conclusions: The use of AngioJet rheolytic thrombectomy and adjunctive local thrombolysis or stenting, or both, under
filter protection, is safe and effective for the management of severe thromboembolic complications occurring in the
femoropopliteal and infrapopliteal arteries during peripheral endovascular procedures. ( J Vasc Surg 2012;56:1308-16.)
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fAcute thromboembolism is considered a potential
disastrous complication of peripheral endovascular revas-
cularization procedures. The actual rate of distal athero-
thrombotic microembolization during endovascular
procedures of the infra-aortic arteries has been reported
to be 98%; however, the incidence of symptomatic,
angiographically evident thromboembolic events ranges
from 1.6% to 3%.1-4 Minimally invasive management
options include catheter-based percutaneous aspiration
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1308hrombectomy (PAT) or thrombolysis, or both, as well
s mechanical thrombectomy using dedicated peripheral
rterial percutaneous thrombectomy devices.5,6
The AngioJet Rheolytic Thrombectomy System
Possis Medical, Minneapolis, Minn) is a potent hydro-
ynamic thrombus macerating and removal system that
s Conformité Européene marked for peripheral arterial
pplications. The mechanism of action is based on the
ernoulli principle and the Venturi effect, and it has
rovided satisfactory results in the management of acute
imb ischemia (ALI).7,8 However, data are lacking on the
se of the AngioJet catheter in the clinical setting of
cute thromboembolism during percutaneous endovas-
ular procedures. The aim of this study was to investigate
he clinical efficacy of intraprocedural AngioJet rheolytic
hrombectomy for the management of severe acute
hromboembolism of the femoropopliteal and distal in-
rapopliteal arteries during peripheral angioplasty, with
r without stenting.
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This study was approved by the Institutional Review
Board of the Hospital’s Ethical and Scientific Committee.
Patients. For the interval between January 2000 and
January 2011, our hospital’s database was interrogated for
all patients with clinically or angiographically evident acute
thromboembolism that occurred during peripheral angio-
plasty, with or without stenting procedures. No endovas-
cular interventions (ie, atherectomies) other than angio-
plasty and stenting were performed during the study
period.
Our department prospectively maintains a dedicated elec-
tronic database that registers all procedural and follow-up
details of patients undergoing endovascular procedures. This
study’s data retrieval was performed by one resident in radiol-
ogy (G.F.) and one interventional radiologist (S.S.) using
specific keywords: complications, peripheral angioplasty, stent-
ing, embolic events, thrombosis, thromboembolism, AngioJet,
mechanical thrombectomy, percutaneous aspiration thrombec-
tomy, PAT, thrombolysis, and amputation. The handwritten
medical records were also analyzed.
The study included all patients treated with intraproce-
dural, infrainguinal (femoropopliteal or infrapopliteal, or
both), AngioJet rheolytic thrombectomy for the manage-
ment of these acute thromboembolic events. The study
excluded occlusive events of the treated vessels detected a
few days after the procedure. Baseline patient demograph-
ics and procedural details were analyzed. The procedural
technical outcome was classified using an angiographic
Thrombolysis in Myocardial Infarction (TIMI)-based flow
grading system, modified for the peripheral arterial vascu-
lature as follows:
● Grade 0 (no perfusion): no antegrade flow beyond the
point of occlusion.
● Grade 1 (penetration without perfusion): contrast me-
dia passes beyond the area of obstruction with delay
but fails to opacify the entire arterial bed distal to the
obstruction during digital subtraction angiography
(DSA).
● Grade 2 (partial perfusion): contrast material passes
across the obstruction and opacifies the arterial bed
distal to the obstruction. However, the rate of entry of
contrast material into the vessel distal to the obstruc-
tion or its rate of clearance from the distal bed (or
both) is perceptibly slower than its entry into or clear-
ance from comparable areas not perfused by the previ-
ously occluded vessel (ie, the arterial bed proximal to
the obstruction).
● Grade 3 (complete perfusion): antegrade flow into the
obstruction as well as distal clearance outflow is de-
tected during DSA as rapid as from an uninvolved
artery in the same leg.9
Study end points. The indication for mechanical
thrombectomy was a clinically (any or all of acute onset of
target limb pain, diminished limb temperature, loss of
pulses) or angiographically evident intraprocedural acute thromboembolic event. The study’s primary end points
ere procedural technical success, defined as the complete
evascularization of the acutely occluded vessel (TIMI
rade 3); clinical success, defined as the absence of death or
eriprocedural (60 days) amputation (major or minor); and
rocedure-related complication rates, defined as major or
inor according to published international guidelines.10
rocedure-related complications included hemoglobin-
ria, acute renal failure or renal dysfunction, and distal
mbolic shower after the AngioJet application.
Secondary end points included embolized vessel pri-
ary patency (EVPP) and overall patient survival. EVPP
as defined as the existence of a nonoccluded target vessel
ssessed with DSA, computed tomography angiography, or
uplex ultrasound imaging and no need for any additional
linically driven repeat interventional or surgical procedure
ithin the previously treated vessel. Follow-up was per-
ormed through regular clinical visits and imaging using
uplex ultrasound imaging, DSA, or computed tomogra-
hy angiography at 3, 6, 12 months and yearly thereafter, as
ell as telephone interviews.
Statistical analysis. All statistical analysis was per-
ormed using GraphPad PRISM 5 software (GraphPad,
an Diego, Calif). Discrete variables are stated as counts
nd percentages, and continuous variables are expressed as
edians and interquartile ranges (25th-75th percentiles) or
s means standard error. Kaplan-Meier life-table analysis
as used for calculation of the target vessel primary patency
nd patient survival.
Thrombectomy technique. All patients received dual-
ntiplatelet therapy with clopidogrel (75 mg/d) and acetylsal-
cylic acid (100 mg/d) for at least 3 days before the procedure.
n intra-arterial bolus dose of heparin (5000 IU) was admin-
strated after sheath insertion and continued at 1000 U/h
uring the procedure.
Our technique for the management of intraprocedural
able I. Baseline demographics
No (%) or
ariable mean  SE
atients 14 (100)
imbs 14 (100)
ale sex 11 (78.5)
ge, years 72  7
ardiac disease 3 (21.4)
iabetes 7 (50)
moking 7 (50)
enal disease 1 (7.1)
yperlipidemia 8 (57.1)
ypertension 11 (78.5)
utherford classification
Category 3 4 (28.6)
Category 4 5 (35.7)
Category 5 4 (28.6)
Category 6 1 (7.1)
LI 10 (71.4)
LI, Critical limb ischemia; SE, standard error.hromboembolic complications is primarily based on the
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November 20121310 Spiliopoulos et alapplication of PAT using large-bore 6F to 8F, single end-
hole guide-catheters, and aspiration with a 50-mL lure-lock
syringe. In cases of failure or inadequate incomplete recan-
alization, further mechanical thrombectomy is performed
using the AngioJet device. However, in thromboembolic
events characterized by a large-volume thrombus burden,
primary rheolytic thrombectomy is performed.
The AngioJet exploits the Venturi-Bernoulli effect
(pressure in a fluid decreases as velocity increases) as the
directed high-velocity saline jets create a powerful vacuum
effect (600 mm Hg) that draws the fragmented thrombus
into the side holes of the catheter. A power pulse delivery
function is also available. The minimum vessel diameter in
which the AngioJet can be used is 2 mm (maximum, 20
mm), whereas catheters with up to 140-cm effective length
are available, allowing its application even in the arterial bed
below the ankle.
An adjunctive intra-arterial infusion of thrombolytic
agent was infused in minimal doses in instances of distal
foot microcirculatory embolization, and stents were used to
entrap any remaining intraluminal thromboembolic mate-
rial that could jeopardize an adequate limb perfusion.
Power pulse delivery was not used. Urokinase was admin-
istrated adjunctively to mechanical thrombectomy, as bolus
doses of 100,000 IU, just above the remaining thrombus.
A peripheral protection device (filter) was used to avoid
embolic showers during thrombectomy or during addi-
tional stenting, whenever this was technically feasible. The
protection filter used was the Spider Embolic Protection
Device, a self-expanding, heparin-coated, conical-shaped,
nitinol basket (ev3Inc, Plymouth, Minn). The device is
available in diameters from 3 to 7 mm and was delivered 2
to 3 cm distally to the occluded arterial segment, preferably
Fig 1. Images show (A) preprocedural digital subtract
acute embolization of the distal segment of the posterior
occluded arterial segment at the level of the ankle,
recanalized distal posterior tibial artery.immediately after the confirmation of the occlusive event. If ahis was not possible for technical reasons, filter positioning
as performed after the first rheolytic thrombectomy pas-
age to prevent further embolic showers during eventual
nal spot stenting. Filter delivery and retrieval was per-
ormed over a 0.014-inch wire through a low-profile deliv-
ry catheter.
Nitroglycerine was used for distal vasospasm. Periph-
ral endovascular procedures in our department are per-
ormed under local anesthesia, with or without intravenous
entanyl (50 to 100 g), so that the patient can collaborate
nd respond to painful stimulus.
ESULTS
During a 12-year period in our department, 3147
eripheral percutaneous angioplasty procedures, with or
ithout stenting, were performed. Of these procedures, 18
0.57%) presented with intraoperative, clinically or angio-
raphically evident distal thromboembolic, and 14 (77.7%)
f these were managed using the AngioJet catheter system.
n the remaining four (22.2%), PAT or intra-arterial local
hrombolysis, or both, were sufficient, and therefore these
atients were excluded from the study. Demographic data
nd the indication for treatment are presented in Table I.
o patients presented with acute or subacute peripheral arte-
ial disease. Critical limb ischemia (CLI) was present in 10 of
4 (71.5%), and limb-threatening ALI developed in all 14
100%). One patient (7.1%) was later diagnosed with idio-
athic thrombocytosis.
The initially treated arteries included one external iliac
rtery, one anterior tibial artery, 11 femoropopliteal arteries,
nd one femoropopliteal polytetrafluoroethylene (PTFE)
raft. All baseline lesions were occlusions. The AngioJet was
giography (DSA) of the distal posterior artery, (B) an
l artery, (C) the AngioJet catheter operating within the
D) post-AngioJet thrombectomy demonstrating theion an
tibia
and (pplied in 21 native arteries (13 infrapopliteal, three femoro-
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Volume 56, Number 5 Spiliopoulos et al 1311popliteal, and six popliteal arteries) and one above-knee fem-
oropopliteal PTFE synthetic graft.
Three of 14 cases (21.4%) underwent AngioJet throm-
bectomy due to extensive thromboembolism involving the
entire femoropopliteal axis, whereas in 11 (78.6%), who
had less extensive events, rheolytic thrombectomy was ap-
plied after a failed initial intraprocedural PAT and intra-
arterial local thrombolysis attempt. The AngioJet in eight
procedures (57.1%) was applied in the distal third of the
tibial vessels and in the below-ankle arterial bed (Fig 1).
Adjunctive, intra-arterial, catheter-directed, local thrombo-
lytic infusion of urokinase (range, 100,000-650,000 IU) was
used in nine of 14 cases (64.3%). Protection filters were used
during mechanical thrombectomy or post-thrombectomy an-
gioplasty in six (42.8%) to avoid further thrombus embolization.
Macroscopically visible material was detected in four of the
six filters (66.6%). Microscopic analysis showed this mate-
rial mainly consisted of platelets, erythrocytes, inflamma-
tory cells, extracellular matrix, endothelial cells, smooth
muscle cells, foam cells, and cholesterol clefts.
Adjunctive clot trapping using stenting was used in six
of 14 procedures (42.8%). A total of 20 stents were de-
ployed in 11 of 22 arteries (50.0%), and 11 (55%) of these
stents were used to restrain the embolic material on the
vessel wall (seven in the femoropopliteal axis and four in the
infrapopliteal arteries). All stents used in the femoropopli-
teal axis and external iliac artery were self-expandable,
whereas self-expandable (2 of 4 [50%]) and sirolimus-
eluting balloon-expandable stents (2 of 4 [50%]) were
deployed in the below-knee arteries. The remaining nine of
20 stents were used due to suboptimal angioplasty (elastic
recoil resulting in a 30% remaining stenosis or flow-
limiting dissection, or both).
A completion angiogram was used to assess status of
runoff vessels. In the cases where adjunctive lysis or stent-
ing, or both, were needed to restore adequate blood flow, a
TIMI grade of 2 was noted after the AngioJet application.
Lesion characteristics and procedural details are analytically
presented in Table II. Technical and clinical success oc-
curred in 13 of 14 cases (92.8%). In one patient at Ruther-
ford 5 CLI after the acute total occlusion of the femoro-
popliteal and the anterior tibial artery, a grade 2 flow was
accomplished using the AngioJet, intra-arterial lysis, and
selective spot stenting (patient 3; Table II). The 24-hour
duplex ultrasound assessment detected a total reocclusion
of the femoropopliteal axis and anterior tibial artery, and
according to the evaluation of a senior vascular surgeon, a
major above-knee amputation had to be performed 3 days
later (1 of 14 [7.1%]). Gangrene resulted in one (7.1%)
prescheduled, non-procedure-related minor amputation of
the first toe 1 week after the procedure.
Mean follow-up was 38.1  49.0 months (range,
3-138 months). One of 14 patients (7.1%) was lost to
follow-up after the 3-month assessment. The EVPP rate
was 67.8% at 6 months and 50.9% at 1 year, overall patient
survival was 53.5% 23.4%, and limb salvage was 92.3%
7.3% after up to 11.5 years of follow-up, as estimated by aaplan-Meier analysis (Fig 2). Three patients died during
he follow-up of causes not related to the procedure, com-
rising one each of respiratory infection/cardiorespiratory
ailure, major ischemic stroke, and heart failure. No hemo-
lobinuria or renal dysfunction or failure was noted. Minor
omplications included two puncture-site hematomas
14.2%). There were no procedure-related minor amputa-
ions, and one procedure-related major above-knee ampu-
ation (7.1%) was required in the single failed case.
ISCUSSION
Although rare, acute thromboembolic events during
eripheral percutaneous transluminal angioplasty and
tenting are a limb-threatening complication necessitating
mmediate treatment. The rate of clinically evident throm-
oembolism in this study was 1%, considerably less than
reviously reported.4,7 Possible explanations of this inci-
ence discrepancy include the routine use of peripheral
rotection devices (filters) whenever a marginally chronic
esion (3- to 6-month onset of symptoms) was suspected,
he use of primary stenting in iliac occlusions, and the
rowing experience of our department in peripheral endo-
ascular procedures.11 In addition, this study also included
atients with only severe ischemia as a result of emboliza-
ion. Of note, all instances of severe limb-threatening acute
rterial thromboembolism occurred during the endovascu-
ar treatment of long occlusions.
Occlusions and the hypercoagulative status detected in
ne patient were the only factors that could explain these
vents, because none of the patients presented with clinical
r angiographic evidence of thrombus before procedure
nd all patients were adequately anticoagulated with an
ntra-arterial bolus dose of heparin (5000 IU) administered
fter sheath insertion and 1000 IU/h during the proce-
ure. In addition, because these were prescheduled proce-
ures, dual-antiplatelet therapy with clopidogrel (75
g/d) and acetylsalicylic acid (100 mg/d) was adminis-
rated for at least 3 days before the procedure. Moreover, all
atients presented with chronic disease, and there were no
linical symptoms suggesting acute or subacute disease.
The sudden occlusion of the major supplier of
he arterial flow to the foot results in clinically evident
evere acute ischemia. In this series, all patients experienced
cute pain after the occlusion, whereas in most patients, the
everity of the ischemic event was also evident due to a
ulseless, cold foot. To avoid amputation, minimally inva-
ive options include PAT, intraprocedural local thrombol-
sis, or the continuation of catheter-directed thrombolysis
or at least 12 to 16 hours.2,11 Our department treats all
ngiographically evident thromboembolic events during
eripheral endovascular procedures because we believe that
ven clinically insignificant occlusive events can compro-
ise future limb salvage. From our experience, asymptom-
tic events are usually caused by a low volume of material
hat allows some blood flow to the distal limb and can be
ealt with by any or all of PAT, local lysis, or focal stenting,
nd the use of rheolytic thrombectomy is rarely necessary in
s
a
a
a
l
e
r
s
i
s
c
o
w
h
p
u
fi
w
h
w
JOURNAL OF VASCULAR SURGERY
November 20121312 Spiliopoulos et althese patients. In our database, only two asymptomatic
thromboembolic events were detected that were treated
using PAT and, therefore, were not included in the study.
We routinely perform percutaneous mechanical throm-
bectomy using the AngioJet because its safety and efficacy
in acute arterial thromboembolic events has already been
reported and the device has received the Conformité Euro-
péene mark for the peripheral arteries.12-17 The advantages
of AngioJet mechanical thrombectomy vs PAT include the
ability to reach distal small-caliber vessels and the possibility
of performing multiple thrombectomy over-the-wire pas-
sages without losing the wire access through the lesion, as
in PAT. Among the drawbacks of thrombolysis are the
potential of severe hemorrhagic complications, the inability
to dissolve hard atheroembolic material, and the necessity
to monitor the patient in a specialized thrombolysis care
unit.7
AngioJet thrombectomy has some limitations, how-
ever, including the increased cost and the potential of
further distal embolism, acute renal failure, and hemoglo-
binuria; moreover, this method resulted in a significant rate
Table II. Procedural details and clinical outcome
Patient Baseline lesion Complication
1
2 SFA occlusion Fempop and anteri
tibial artery TE
3 20 cm fempop occlusion,
1-vessel runoff
Fempop and anteri
tibial artery TE
4 EIA occlusion Anterior tibial and
peroneal artery T
5 SFA occlusion Popliteal artery em
6 SFA occlusion Fempop, thrombos
tibial trifurcation
embolism
7 SFA occlusion Posterior tibial arte
embolism
8 SFA occlusion Fempop, TB artery
9 SFA occlusion Peroneal, posterior
artery TE
10 Anterior tibial artery occlusion Anterior tibial arter
11 Fempop occlusion Fempop thrombos
12 Fempop synthetic graft
occlusion
Fempop graft and
anterior tibial art
13 SFA occlusion Anterior tibial arter
14 SFA occlusion Popliteal artery em
ALI, Acute limb ischemia; EIA, external iliac artery; Fempop, femorop
thromboembolism; TIMI, Thrombolysis in Myocardial Infarction study.of stenting (Fig 3). In instances where thrombus remains, tome authors have proposed short-term overnight intra-
rterial thrombolysis as an alternative to stenting, thus
voiding the placement of an expensive stent, sometimes in
previously normal vessel, a fact that could compromise
ong-term vessel patency.7 AngioJet thrombectomy with
ventual adjunctive spot stenting provides a more rapid
eperfusion, and in this study, regardless of the use of a
mall amount of adjunctive thrombolytic, the sheath was
mmediately removed after the procedure and hemostasis
uccessfully performed with manual compression or with a
losure device. Only two small puncture-site hematomas
ccurred.
In all successful procedures, no additional management
as required, and the patients were discharged from the
ospital the next day, as described by our department’s
rotocol. We followed the manufacture’s indication not to
se the device for more than 10 minutes in a flowing blood
eld to avoid excessive hemolysis. No hemolytic anemia
as noted. Notably, distal embolization rates of up to 9.8%
ave been described after AngioJet thrombectomy,
hereas the perforation rate after mechanical thrombec-
Symptoms
AngioJet
application
Limb-threatening ALI (acute
pain, cold foot)
Popliteal, TBA, posterior
tibial artery
Limb-threatening ALI (acute
pain, cold foot)
Fempop, anterior tibial
artery
Limb-threatening ALI (acute
pain, absent pulses)
Fempop, anterior tibial,
pedal artery
Limb-threatening ALI (acute
pain, absent pulses, cold
foot)
Anterior tibial, pedal,
and distal peroneal
artery
Limb-threatening ALI (pain,
absent pulses, cold leg)
Supragenicular and
infragenicular popliteal
artery
Limb-threatening ALI (acute
pain, absent pulses, cold
leg)
Fempop, anterior tibial
TBA/distal posterior
tibial arteries
Limb-threatening ALI (acute
pain, absent pulses)
Distal posterior tibial
artery
Limb-threatening ALI (acute
pain, absent pulses)
Fempop, TBA arteries
l Limb-threatening ALI (acute
pain, absent pulses, cold
foot)
Peroneal artery, posterior
tibial artery
Limb-threatening ALI (acute
pain, absent distal pulses)
Anterior tibial, pedal
artery
Limb-threatening ALI (acute
pain, blue toe syndrome)
Fempop artery
E
Limb threatening ALI (acute
pain, no distal pulses)
Fempop graft, anterior
tibial, pedal artery
Limb-threatening ALI (acute
pain, blue toe syndrome)
Anterior tibial, pedal
artery
Limb-threatening ALI (acute
pain, cold leg, no popliteal
or distal pulses)
Popliteal artery
al axis; SFA, superficial femoral artery; TBA, tibioperoneal artery; TE,or
or
E
bolism
is,
ry
TE
tibia
y
is
ery T
y TE
bolism
opliteomy ranges from 0% to 4%.7,18 To cope with this “embolic
i
w
t
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cedural, catheter-based, local thrombolysis selectively into
the distal pedal microvasculature and the use of peripheral
protection filters whenever this is technically feasible (Fig
Fig 2. Kaplan-Meier analysis plots show (A) target vess
indicate the standard error.
Table II. Continued.
Adjunctive local
thrombolysis Stent used
No Initial segment of posterior
tibial artery
250,000 IU urokinase SFA, popliteal, anterior
tibial arteries
200,000 IU urokinase Yes (distal anterior tibial
artery
No No
300,000 IU urokinase No
100,000 IU urokinase Yes (TBA and posterior
tibial arteries
overlapping)
100,000 IU urokinase No
200,000 IU urokinase Yes (popliteal and TBA
arteries overlapping)
650,000 IU urokinase Yes
No No
No Yes (SFA and popliteal
artery)
No No
100,000 IU urokinase No
100,000 IU urokinase Yes (popliteal artery)3). Ideally, filters are positioned before thrombectomy and, ef this is not technically possible, before angioplasty with or
ithout stenting of the remaining underlying lesion or
hrombus entrapment on the arterial wall using stenting.
Stents used for this particular reason are usually self-
imary patency and (B) patient survival. The dotted lines
Technical success Clinical success
Yes Yes
Yes Yes
No (TIMI grade 2) No (major amputation)
Yes Yes
Yes Yes
Yes Yes
ϒes Yes
ϒes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes No (minor amputation)
Yes Yesel prxpandable, bare-metal stents, and no postdilatation should
f
u
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November 20121314 Spiliopoulos et albe performed to avoid thrombus “squeezing” through the
metallic mesh and further distal embolic events. Nonetheless,
in two cases of infrapopliteal thromboembolism, bal-
Fig 3. A, Angiographic image demonstrates the sub
dedicated Outback LTD (Cordis, Miami Lakes, Fla) re-e
popliteal artery (dashed arrow). B, Selective duplex subs
dural occlusion of the tibial trifurcation after balloon ang
tomy of the anterior tibial artery (arrow) is shown under fi
thrombectomy indicating remaining occlusive material in
(dashed arrow) tibial arteries. E, Final DSA image demon
The remaining thrombus was removed from the anter
adjunctive local thrombolysis, while a sirolimus-eluting s
posterior tibial artery wall (arrow). F, Final DSA image dloon-expandable sirolimus-eluting stents were success- bully deployed using a moderate inflation technique,
nder peripheral filter protection. Although the nature
f the occlusive material is difficult to distinguish, we
al recanalization of the femoropopliteal axis using a
catheter (arrow). Note the 0.014-inch guidewire in the
on angiography (DSA) image of the abrupt intraproce-
sty of the femoropopliteal axis. C, AngioJet thrombec-
rotection (dashed arrow). D, DSA image after AngioJet
roximal one-third of the anterior (arrow) and posterior
s the patency of the anterior and posterior tibial arteries.
bial artery using one additional AngioJet passage and
was used to trap the atheroembolic material against the
nstrates a two-vessel runoff.intim
ntry
tracti
iopla
lter p
the p
strate
ior ti
tentelieve that atheroembolism occurred in three instances,
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ther supporting this notion was that AngioJet thrombec-
tomy and adjunctive lysis were not sufficient in dissolving
the small amount of occlusive material, probably due to
its solid, durable composition that characterizes athero-
emboli, and stents were used to trap these emboli on the
vessel wall.
Interestingly, thrombus migration occurred in one in-
stance of femoropopliteal acute occlusion, filling the pro-
tective filter that was positioned in the distal segment of the
popliteal artery just above the tibial trifurcation. During
filter retrieval, some thrombotic material was “squeezed”
by the retrieving catheter out of the filter, inciting distal
pedal embolization. Additional pharmacomechanical pedal
thrombolysis (AngioJet plus 100,000 IU urokinase) was
implemented, resulting in an excellent final TIMI grade 3
antegrade flow.
The technical success rate of almost 93% of this imme-
diate, intraprocedural management technique, using the
powerful rheolytic thrombectomy with occasional adjunc-
tive fibrinolysis, filter protection, or stenting, should be
considered very satisfactory because all of these thrombo-
embolic cases were severe limb-threatening events with
acute clinical manifestation of ALI. The only technical
failure resulted in a major above-knee amputation. The
estimated survival rate was 53.5% at 11.5 years of follow-
up, according to the Kaplan-Meier statistical model. Con-
sidering that CLI was present in almost 72% of the study
population, this survival rate is in accordance with previ-
ously published data and international guidelines.19
Although the small sample number precluded a valid
statistical analysis to determine any possible factors influ-
encing outcomes, procedural success (TIMI grade 3) was
associated with complete thrombus removal from the lu-
men in combination with a sufficient arterial inflow and
outflow, because in the only case in which it was not
possible (TIMI grade 2), the treated arteries rethrombosed
after 24 hours, despite the prescribed prophylactic anti-
platelet therapy. At this point it is of the utmost importance
to delineate that a rigorous postprocedural medication
protocol and clinical and imaging follow-up should be
provided to guarantee long-term clinical success.
Data regarding optimal postprocedural antiplatelet
protocol are currently missing.19,20 All patients included in
this study received triple-antiplatelet therapy with low-
molecular-weight heparin, clopidogrel (75 mg), and aspirin
(100 mg/d) immediately after the procedure for 14 days,
followed by a dual-antiplatelet regimen (clopidogrel/
aspirin) for 6 months and lifelong single-drug therapy
(clopidogrel or aspirin).
Among the study’s limitations are that although a
careful audit in the department’s electronic database was
performed and patients’ archives were scrutinized, a retro-
spective analysis cannot exclude a recall bias generated from
the lack of ability to detect all patients treated during the
12-year period.ONCLUSIONS
In most cases, infrainguinal limb-threatening thrombo-
mbolism that may occur during infra-aortic endovascular
ngioplasties, with or without stenting, is a very uncom-
on but difficult clinical scenario. The intraprocedural
pplication of AngioJet rheolytic thrombectomy is very
seful for re-establishing flow expeditiously; however, ad-
unctive use of intraoperative thrombolysis, stents, and
lter protection is frequently needed to achieve acceptable
utcomes.
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